Browse our anti-HRAS (HRAS) Antibodies

Full name:
anti-V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog Antibodies (HRAS)
On are 143 V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) Antibodies from 25 different suppliers available. Additionally we are shipping HRAS Proteins (19) and HRAS Kits (17) and many more products for this protein. A total of 190 HRAS products are currently listed.
AI929937, C-BAS/HAS, c-H-ras, c-Ha-ras, C-HA-RAS1, c-rasHa, CTLO, H-ras, H-RASIDX, Ha-ras, HAMSV, Harvey-ras, hras, Hras-1, HRAS1, K-ras, Ki-ras, Kras-2, Kras2, N-RAS, p21B, ras, RASH1, zgc:110250

Most Popular Reactivities for anti-HRAS (HRAS) Antibodies

Select your species and application

anti-Human HRAS Antibodies:

anti-Rat (Rattus) HRAS Antibodies:

anti-Mouse (Murine) HRAS Antibodies:

All available anti-HRAS Antibodies

Go to our pre-filtered search.

Top referenced anti-HRAS Antibodies

  1. Human Polyclonal HRAS Primary Antibody for EIA, IF - ABIN952792 : Ma, Liu, Wu, Terada: p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior. in Oncogene 2010 (PubMed)
    Show all 5 references for 952792

  2. Human Monoclonal HRAS Primary Antibody for EIA, WB - ABIN238418 : Prior, Harding, Yan, Sluimer, Parton, Hancock: GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. in Nature cell biology 2001 (PubMed)
    Show all 5 references for 238418

  3. Human Polyclonal HRAS Primary Antibody for IF, WB - ABIN655622 : van Engen-van Grunsven, van Dijk, Ruiter, Klaasen, Mooi, Blokx: HRAS-mutated Spitz tumors: A subtype of Spitz tumors with distinct features. in The American journal of surgical pathology 2010 (PubMed)
    Show all 4 references for 655622

  4. Human Polyclonal HRAS Primary Antibody for EIA, WB - ABIN360066 : Coats, Booden, Buss: Transient palmitoylation supports H-Ras membrane binding but only partial biological activity. in Biochemistry 1999 (PubMed)
    Show all 3 references for 360066

  5. Human Polyclonal HRAS Primary Antibody for IF, IHC (p) - ABIN392183 : Maemoto, Yumoto, Ibata, Torizuka, Ozawa, Tatsumi, Hashido, Morikawa, Maeda, Imai: Mutational analysis of HRAS and KRAS genes in oral carcinoma cell lines. in Odontology / the Society of the Nippon Dental University 2012 (PubMed)
    Show all 2 references for 392183

More Antibodies against HRAS Interaction Partners

Cow (Bovine) V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) interaction partners

  1. Data demonstrate that H-Ras activation is important in the activation of the specific signaling events leading to the accelerated retinal capillary cell apoptosis in hyperglycemic conditions.

  2. Activation of H-Ras and its downstream signaling pathway in the retina and its vasculature could be under the control of superoxide, and H-Ras activation in diabetes can be prevented by inhibiting superoxide accumulation.

  3. Thrombospondin 1 (show THBS1 Antibodies), fibronectin (show FN1 Antibodies), and vitronectin (show VTN Antibodies) are differentially dependent upon RAS, ERK1/2 (show MAPK1/3 Antibodies), and p38 (show MAPK14 Antibodies) for induction of vascular smooth muscle cell chemotaxis.

Zebrafish V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) interaction partners

  1. Kita driven expression of oncogenic HRAS leads to early onset and highly penetrant melanoma in zebrafish

Human V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) interaction partners

  1. Knockdown of forkhead Box M1 (FoxM1 (show FOXM1 Antibodies)) reduced Prx (show PRDX6 Antibodies) II levels in H-ras(G12V)-hepatocellular carcinoma (HCC (show FAM126A Antibodies)) cells, indicating FoxM1 (show FOXM1 Antibodies) as a direct transcription factor of Prx (show PRDX6 Antibodies) II in HCC (show FAM126A Antibodies).

  2. we found that ectopic expression of oncogenic KRas and HRas in cells resulted in elevated CIB1 (show CIB1 Antibodies) expression. We previously described the Ca(2 (show CA2 Antibodies)+)-myristoyl switch function of CIB1 (show CIB1 Antibodies), and its ability to facilitate agonist-induced plasma membrane localisation of sphingosine kinase 1 (SK1 (show SPHK1 Antibodies)), a location where SK1 (show KCNN1 Antibodies) is known to elicit oncogenic signalling.

  3. Data suggest that isoform-specific sequences in the allosteric lobes of HRAS, KRAS, and NRAS (show NRAS Antibodies) have an impact on biocatalysis (kinetics of GTP (show AK3 Antibodies) hydrolysis) and interaction with c-Raf (show RAF1 Antibodies) kinase, which must be due to allosteric effects on dynamics and conformational states, given the identical active sites of these isoenzymes.

  4. Data suggest HRas activates both p110alpha and p110delta isoforms; membrane-resident HRas, not soluble HRas, increases membrane recruitment of both p110alpha and p110delta. (HRas = v-Ha-ras Harvey rat sarcoma viral oncogene homolog; p110alpha = class IA phosphoinositide 3-kinases, subunit p110alpha; p110delta = class IA phosphoinositide 3-kinases, subunit p110delta)

  5. Our data suggest that testing for any RAS mutation is unlikely to change the clinical management of thyroid nodules that have indeterminate cytology

  6. Equilibrium dissociation constants were determined for the binding of HRAS, KRAS, NRAS and RRAS2 to the RAS binding (RB) domain of binding proteins.

  7. Studies indicate that RAS proteins were among the first oncogenes identified and are mutationally activated in 30% of all cancer types.

  8. 6 of 7 (86%) malignant ectomesenchymomas had HRAS mutations

  9. RAS-positive thyroid cancer most often demonstrates indolent sonographic features and more commonly associates with lower risk, "indeterminate" cytology.

  10. Studies indicate that the control of spatiotemporal RAS protein signalling show that activation kinetics and subcellular compartmentalisation are tightly coupled to the generation of specific biological outcomes.

Mouse (Murine) V-Ha-Ras Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) interaction partners

  1. KrasG12D-driven proliferation of pancreatic ductal epithelial cells (PDECs) depends on an EGFR (show EGFR Antibodies) signaling loop engaging the oncogenic transcription factor c-MYC (show MYC Antibodies).

  2. median survival of KPIC mice was longer than that of LSL-KrasG12D; Ink4flox/flox; Ptf1/p48 (show PTF1A Antibodies)-Cre mice (KIC) (89 vs 62 days) and shorter than that of KRAS (KrasG12D), TP53 (show TP53 Antibodies) (Trp53R172H/+) and Ptf1/p48 (show PTF1A Antibodies)-Cre (KPC) mice

  3. Loss of N-cadherin in the context of oncogenic K-ras leads to increased pancreatic intraepithelial neoplasia (PanIN) incidence and progression.

  4. p21 (show D4S234E Antibodies)-associated inhibition of early-stage malignant progression and the intense expression in papilloma outgrowths, identifies a novel, significant antagonism between p21 (show D4S234E Antibodies) and ras(Ha)/ROCK2 (show ROCK2 Antibodies)/NF-kappaB (show NFKB1 Antibodies) signalling in skin carcinogenesis.these data show that ROCK2 (show ROCK2 Antibodies) activation induces malignancy in ras(Ha)-initiated/promoted papillomas in the context of p53 (show TP53 Antibodies) loss and novel NF-kappaB (show NFKB1 Antibodies) expression

  5. activating mutations in GNAS and Kras cooperatively promote murine pancreatic tumorigenesis

  6. the Kras(mut (show MUT Antibodies)) allele was heterogenous in primary tumors yet homogenous in metastases, a pattern consistent with activated Kras(mut (show MUT Antibodies)) signaling being a driver of progression to metastasis.

  7. Using an extensive collection of novel murine cell lines we have identified distinct roles for Kras and Pten (show PTEN Antibodies) on MUC1 (show MUC1 Antibodies) and EMT (show ITK Antibodies) in vivo and in vitro. The data has implications for future design of combination therapies targeting Kras mutations, Pten (show PTEN Antibodies) deletions and MUC1 (show MUC1 Antibodies) vaccines.

  8. a potent tumor-suppressive function for Lfng (show LFNG Antibodies)

  9. pancreatic ductal cells, whereas exhibiting relative resistance to oncogenic Kras alone, can serve as an effective cell of origin for pancreatic ductal adenocarcinoma in the setting of gain-of-function mutations in p53 (show TP53 Antibodies)

  10. In vivo treatment of the KRAS(G12D)-induced Langerhans cell histiocytosis -like mouse with the cholesterol-lowering drug atorvastatin ameliorated the pathology, implicating statins as potential therapeutics against a subset of pulmonary Langerhans cell histiocytosis.

HRAS Antigen Profile

Antigen Summary

This gene belongs to the Ras oncogene family, whose members are related to the transforming genes of mammalian sarcoma retroviruses. The products encoded by these genes function in signal transduction pathways. These proteins can bind GTP and GDP, and they have intrinsic GTPase activity. This protein undergoes a continuous cycle of de- and re-palmitoylation, which regulates its rapid exchange between the plasma membrane and the Golgi apparatus. Mutations in this gene cause Costello syndrome, a disease characterized by increased growth at the prenatal stage, growth deficiency at the postnatal stage, predisposition to tumor formation, mental retardation, skin and musculoskeletal abnormalities, distinctive facial appearance and cardiovascular abnormalities. Defects in this gene are implicated in a variety of cancers, including bladder cancer, follicular thyroid cancer, and oral squamous cell carcinoma. Multiple transcript variants, which encode different isoforms, have been identified for this gene.

Alternative names and synonyms associated with HRAS

  • Harvey rat sarcoma viral oncogene homolog (hras) antibody
  • v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS) antibody
  • v-Ha-ras Harvey rat sarcoma viral oncogene homolog a (hrasa) antibody
  • neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) antibody
  • v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) antibody
  • Harvey rat sarcoma viral oncogene homolog (HRAS) antibody
  • Harvey rat sarcoma virus oncogene (Hras) antibody
  • Harvey rat sarcoma virus oncogene 1 (Hras1) antibody
  • v-Ha-ras Harvey rat sarcoma viral oncogene homolog (Hras) antibody
  • v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras) antibody
  • AI929937 antibody
  • C-BAS/HAS antibody
  • c-H-ras antibody
  • c-Ha-ras antibody
  • C-HA-RAS1 antibody
  • c-rasHa antibody
  • CTLO antibody
  • H-ras antibody
  • H-RASIDX antibody
  • Ha-ras antibody
  • HAMSV antibody
  • Harvey-ras antibody
  • hras antibody
  • Hras-1 antibody
  • HRAS1 antibody
  • K-ras antibody
  • Ki-ras antibody
  • Kras-2 antibody
  • Kras2 antibody
  • N-RAS antibody
  • p21B antibody
  • ras antibody
  • RASH1 antibody
  • zgc:110250 antibody

Protein level used designations for HRAS

v-Ha-ras Harvey rat sarcoma viral oncogene homolog , small G-protein H-Ras , Harvey ras 1 , p19 H-RasIDX protein , GTPase HRas (Transforming protein p21) (H-Ras-1) (c-H-ras) , xRAS1 , GTPase HRas , Transforming protein p21 , neuroblastoma ras oncogene , GTP- and GDP-binding peptide B , H-Ras-1 , Ha-Ras1 proto-oncoprotein , Ras family small GTP binding protein H-Ras , c-has/bas p21 protein , c-ras-Ki-2 activated oncogene , p21ras , transformation gene: oncogene HAMSV , transforming protein p21 , Harvey ras1 protein , Harvey rat sarcoma viral (v-Ha-ras) oncogene homolog , H-ras 1 protein , c-Ha-ras p21 protein , c-Ha-ras transgene , transforming protein P21 , GTPase NRas , transforming protein N-Ras , c-H-ras , v-Ha-ras Harvey rat sarcoma viral oncogene-like protein , ras p21 , GTPase KRas , K-Ras 2 , Kirsten rat sarcoma oncogene 2, expressed , c-K-ras , c-Ki-ras , p21 protein

399406 Xenopus laevis
466302 Pan troglodytes
513012 Bos taurus
549757 Xenopus (Silurana) tropicalis
550286 Danio rerio
698830 Macaca mulatta
733587 Sus scrofa
100222058 Taeniopygia guttata
100227892 Taeniopygia guttata
3265 Homo sapiens
293621 Rattus norvegicus
15461 Mus musculus
100739349 Sus scrofa
100735038 Cavia porcellus
396229 Gallus gallus
403735 Canis lupus familiaris
100298939 Bos taurus
101104357 Ovis aries
16653 Mus musculus
Selected quality suppliers for anti-HRAS (HRAS) Antibodies
Did you look for something else?